Hara Capital LLC Takes $2.58 Million Position in Novo Nordisk A/S $NVO

Hara Capital LLC bought a new position in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 46,417 shares of the company’s stock, valued at approximately $2,576,000. Novo Nordisk A/S comprises about 1.5% of Hara Capital LLC’s investment portfolio, making the stock its 17th biggest holding.

A number of other hedge funds have also made changes to their positions in the company. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC grew its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares during the last quarter. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 2nd quarter valued at $39,000. Finally, Ballentine Partners LLC raised its position in Novo Nordisk A/S by 23.6% in the 2nd quarter. Ballentine Partners LLC now owns 35,629 shares of the company’s stock valued at $2,459,000 after purchasing an additional 6,801 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $62.28 on Friday. The firm has a market cap of $278.08 billion, a price-to-earnings ratio of 18.10 and a beta of 0.66. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average price of $51.85 and a 200 day moving average price of $54.85.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. CICC Research initiated coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. HSBC restated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $56.21.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.